Skip to main content
. 2016 Oct 18;6:35314. doi: 10.1038/srep35314

Table 2. Absolute number of different T cells populations of multiple sclerosis patients (MS) with or without fingolimod therapy.

  MS patients without fingolimod therapy
MS patients with fingolimod therapy
without DMD with IFN-β relapse-free relapse-experienced
in rem at rel in rem at rel in rem at rel 3 month after rel
No. of patients 5 5 11 4 11 4 4
Lymphocytes/μl 1548 ± 378.1 1284 ± 424.0 1437 ± 534.7 1795 ± 335.2 433.6 ± 196.9 425 ± 152.3 455 ± 151.7
T cells/μl
Total 1281 ± 386 964.3 ± 312.9 1134.9 ± 431.4 1377.6 ± 344.6 162.8 ± 155.8 122.7 ± 45.9 117.7 ± 83.3
CD56+cells/μl
 CD3+ 43.9 ± 24.0 16.6 ± 11.0 29.4 ± 34.0 14.7 ± 14.0 20.1 ± 23.0 71.1 ± 36.0 56.9 ± 43.9
 CD4+ 8.7 ± 4.0 6.3 ± 3.0 3.9 ± 2.0 6.3 ± 7.0 2.8 ± 3.0 10.9 ± 13.0 11.1 ± 11.6
 CD8+ 24.2 ± 15.0 8.8 ± 7.0 21.2 ± 27.0 8.1 ± 7.0 10.5 ± 15.0 40.8 ± 15.0 23.5 ± 10.3

Mean values (± standard deviation) are reported.

Abbreviations are as follows, without DMD: without disease-modifying drug, with IFN-β: with interferon β therapy, rem: remission, rel: relapse.